Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

WuXi AppTec, UK Ltd

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

Efficient use of blood plasma

Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.